Report Detail
Hepatocellular carcinoma (HCC)- Market Insights, Epidemiology and Market Forecast-2028
- RnM3869823 |
- 24 January, 2020 |
- Global |
- 233 Pages |
- DelveInsight |
- Other
DelveInsight’s ‘Hepatocellular carcinoma (HCC)- Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of HCCs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Hepatocellular carcinoma (HCC) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2017–2028
Hepatocellular carcinoma (HCC) - Disease Understanding and Treatment Algorithm
Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer. It is a malignant tumor of hepatocytes, may exhibit any or all of the cytologic and/or architectural characteristics of hepatocellular differentiation, along with features of malignancy. Identification of intercellular bile and/or canaliculi are diagnostic of the cellular origin of the tumor. Hepatocellular Carcinoma (HCC) is the fifth most common cause of cancer, and its incidence is increasing worldwide because of the dissemination of Hepatitis B and C virus infection.
The DelveInsight Hepatocellular carcinoma (HCC) market report gives the thorough understanding of the Hepatocellular carcinoma by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Hepatocellular carcinoma in the US, Europe and Japan.
Hepatocellular carcinoma Epidemiology
The Hepatocellular carcinoma (HCC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Diagnosed Incidence Cases of HCC, Advance Cases of HCC, Gender Specific Incident Cases of HCC, Incidence of HCC based on Aetiology and Incidence of HCC by BCLC stages) scenario of Hepatocellular carcinoma (HCC) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028.
According to DelveInsight, the total number of Incident cases of Hepatocellular carcinoma (HCC) in 7 MM was found to be 105,785 in the year 2017.
Hepatocellular carcinoma Drug Chapters
This segment of the Hepatocellular carcinoma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The treatment is generally recommended at early stage HCC and may not be recommended to treat patients with later stages of disease. These treatments are surgery, radiofrequency ablation, percutaneous ethanol injection, and radiation therapy. Surgical resection, transplantation, ablation, transarterial chemoembolization, and the tyrosine-kinase inhibitors sorafenib, lenvatinib, and regorafenib are the treatments with proven survival benefit. Systemic chemotherapy has marginal activity with associated toxicity and no survival benefit.
Hepatocellular carcinoma Market Outlook
The Hepatocellular carcinoma market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Hepatocellular carcinoma in 7MM was found to be USD 1,841.7 Million in 2017, and is expected to increase during the course of the study period (2017–2028). Among the 7MM, the United States accounts for the largest market size of HCC, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Hepatocellular carcinoma Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017–2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Hepatocellular carcinoma Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Hepatocellular carcinoma Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Hepatocellular carcinoma Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Hepatocellular carcinoma market
• Organize sales and marketing efforts by identifying the best opportunities for Hepatocellular carcinoma market
• To understand the future market competition in the Hepatocellular carcinoma market.
1. Key Insights
2. Hepatocellular Carcinoma Market Overview at a Glance
- 2.1. Market Share (%) Distribution of Hepatocellular Carcinoma in 2017
- 2.2. Market Share (%) Distribution of Hepatocellular Carcinoma in 2028
3. Disease Background and Overview: Hepatocellular Carcinoma
- 3.1. Introduction
- 3.2. Signs and Symptoms
- 3.3. Staging of Hepatocellular Carcinoma
- 3.3.1. Okuda Stage
- 3.3.2. French Classification
- 3.3.3. CLIP Score
- 3.3.4. CUPI Score
- 3.3.5. TNM Stage
- 3.3.6. JIS Staging
- 3.3.7. BCLC Staging System
- 3.4. Etiology and Risk Factors
- 3.5. Pathophysiology
- 3.5.1. HCC progression and driver genes
- 3.5.2. Molecular Pathways involved in HCC
- 3.6. Diagnosis
- 3.7. Diagnostic Guidelines
- 3.7.1. American Association for the Study of Liver Diseases (AASLD) practice guidelines for HCC surveillance and diagnosis
- 3.7.2. European Association for the Study of the Liver (EASL)–European Organization for Research and Treatment of Cancer (EORTC) practice guidelines for HCC surveillance and diagnosis
- 3.7.3. Japanese evidence-based clinical practice guidelines for HCC
- 3.7.4. NCCN (National Comprehensive Cancer Network) Clinical practice Guidelines
4. Epidemiology and Patient Population
- 4.1. Key Findings
- 4.2. Population and Forecast Parameters
- 4.3. Total Diagnosed Incident Cases of HCC in 7MM
5. Country Wise-Epidemiology of HCC
- 5.1. The United States
- 5.1.1. Total Diagnosed Incident cases of HCC in the United States
- 5.1.2. Advance Stage Cases of HCC in the United States
- 5.1.3. Gender Specific Incident Cases of HCC in the United States
- 5.1.4. Incidence of HCC based on Aetiology in the United States
- 5.2. EU5 Countries
- 5.3. Germany
- 5.3.1. Total Diagnosed Incident cases of HCC in Germany
- 5.3.2. Advance Stage Cases of HCC in Germany
- 5.3.3. Gender Specific Incident Cases of HCC in Germany
- 5.3.4. Incidence of HCC based on Aetiology in Germany
- 5.4. France
- 5.4.1. Total Diagnosed Incident cases of HCC in France
- 5.4.2. Advance Stage Cases of HCC in France
- 5.4.3. Gender Specific Incident Cases of HCC in France
- 5.4.4. Incidence of HCC based on Aetiology in France
- 5.5. Italy
- 5.5.1. Total Diagnosed Incident cases of HCC in Italy
- 5.5.2. Advance Stage Cases of HCC in Italy
- 5.5.3. Gender Specific Incident Cases of HCC in Italy
- 5.5.4. Incidence of HCC based on Aetiology in Italy
- 5.6. Spain
- 5.6.1. Total Diagnosed Incident cases of HCC in Spain
- 5.6.2. Advance Stage Cases of HCC in Spain
- 5.6.3. Gender Specific Incident Cases of HCC in Spain
- 5.6.4. Incidence of HCC based on Aetiology in Spain
- 5.7. United Kingdom
- 5.7.1. Total Diagnosed Incident cases of HCC in the United Kingdom
- 5.7.2. Advance Stage Cases of HCC in the United Kingdom
- 5.7.3. Gender Specific Incident Cases of HCC in the United Kingdom
- 5.7.4. Incidence of HCC based on Aetiology in the United Kingdom
- 5.8. Japan
- 5.8.1. Total Diagnosed Incident cases of HCC in Japan
- 5.8.2. Advance Stage Cases of HCC in Japan
- 5.8.3. Gender Specific Incident Cases of HCC in Japan
- 5.8.4. Incidence of HCC based on Aetiology in Japan
6. Treatment Practices
- 6.1. Treatment Goals
- 6.2. Treatment Algorithm based on NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines for Treatment
- 6.3. AASLD Guidelines for the Treatment of Hepatocellular Carcinoma
- 6.3.1. Recommendations
- 6.4. Management guidelines for HCC: European Society for Medical Oncology (ESMO)
- 6.5. Management of Early and Intermediate HCC
- 6.6. Management of Advance Disease
- 6.7. Follow-up, long-term implications & survivorship
7. Unmet Needs
8. Organizations contributing towards HCC
9. Marketed Drug Analysis
- 9.1. Nexavar: Bayer HealthCare
- 9.1.1. Drug Description
- 9.1.2. Regulatory Milestones
- 9.1.3. Generic Availability
- 9.1.4. Clinical Development
- 9.1.5. Safety and Efficacy
- 9.1.6. Product Profile
- 9.2. Miripla: Sumitomo Dainippon Pharma
- 9.2.1. Drug Description
- 9.2.2. Regulatory Milestones
- 9.2.3. Clinical Development
- 9.2.4. Safety and Efficacy
- 9.2.5. Product Profile
- 9.3. Opdivo: Bristol-Myers Squibb
- 9.3.1. Drug Description
- 9.3.2. Regulatory Milestones
- 9.3.3. Clinical Development
- 9.3.4. Safety and Efficacy
- 9.3.5. Product Profile
- 9.4. Pembrolizumab (Keytruda): Merck & Co.
- 9.4.1. Drug Description
- 9.4.2. Regulatory Milestones
- 9.4.3. Clinical Development
- 9.4.4. Safety and Efficacy
- 9.4.5. Product Profile
- 9.5. Stivarga: Bayer Pharma
- 9.5.1. Drug Description
- 9.5.2. Regulatory Milestones
- 9.5.3. Generic Availability
- 9.5.4. Clinical Development
- 9.5.5. Safety and Efficacy
- 9.5.6. Product Profile
- 9.6. Ramucirumab (Cyramza): Eli Lilly and Co.
- 9.6.1. Product Description
- 9.6.2. Other Developmental Activities
- 9.6.3. Clinical Development
- 9.6.4. Safety and Efficacy
- 9.6.5. Product Profile
- 9.7. Cabometyx: Exelixis Inc.
- 9.7.1. Product Description
- 9.7.2. Other Developmental Activities
- 9.7.3. Clinical Development
- 9.7.4. Safety and Efficacy
- 9.7.5. Product Profile
- 9.8. Lenvima: Merck/Eisai
- 9.8.1. Drug Description
- 9.8.2. Regulatory Milestones
- 9.8.3. Clinical Development
- 9.8.4. Safety and Efficacy
- 9.8.5. Product Profile
10. Emerging Therapies
- 10.1. Emerging Drugs Analysis
- 10.1.1. Tislelizumab (BGB-A317): BeiGene
- 10.1.2. Durvalumab (Imfinzi): Astra Zeneca
- 10.1.3. Milciclib: Tiziana Life Sciences
- 10.2. Combinational Drugs Analysis
- 10.3. Failure in Phase III Clinical trials for Hepatocellular Carcinoma
11. Other Promising Candidates
- 11.1. Namodenoson (CF 102): Can-Fite BioPharma
- 11.1.1. Product Description
- 11.1.2. Other Developmental Activities
- 11.1.3. Clinical Development
- 11.1.4. Safety and Efficacy
- 11.1.5. Product Profile
- 11.2. Capmatinib: Eli Lilly and Co.
- 11.2.1. Product Description
- 11.2.2. Other Developmental Activities
- 11.2.3. Clinical Development
- 11.2.4. Safety and Efficacy
- 11.2.5. Product Profile
- 11.3. Palbociclib: Pfizer
- 11.3.1. Product Description
- 11.3.2. Clinical Development
- 11.3.3. Safety and Efficacy
- 11.3.4. Product Profile
- 11.4. ENMD2076: CASI Pharmaceuticals
- 11.4.1. Product Description
- 11.4.2. Other Developmental Activities
- 11.4.3. Clinical Development
- 11.4.4. Safety and Efficacy
- 11.4.5. Product Profile
- 11.5. HCC011: Tera Bio-Pharma
- 11.5.1. Product Description
- 11.5.2. Other Developmental Activities
- 11.5.3. Clinical Development
- 11.5.4. Product Profile
12. Case Studies
- 12.1. Unresectable Hepatocellular Carcinoma
- 12.2. Hepatocellular Carcinoma in a Young Adult
13. Hepatocellular Carcinoma [HCC]: 7MMMarket Analysis
- 13.1. Key Findings
- 13.2. Total Market Size of Hepatocellular Carcinoma (HCC) in 7MM
- 13.3. 7MM Market Size of HCC by Line of Therapies
14. Market Outlook by Country
- 14.1. The United States: Market Outlook
- 14.2. United States Market Size
- 14.2.1. Total Market size of Hepatocellular carcinoma [HCC]
- 14.2.2. Hepatocellular Carcinoma Market Size by Line of Therapies
- 14.2.3. Market Size by First Line of Therapies
- 14.2.4. Market Size by Second Line of Therapies
- 14.3. EU-5 Countries: Market Outlook
- 14.4. Germany Market Size
- 14.4.1. Total Market size of Hepatocellular Carcinoma
- 14.4.2. Hepatocellular Carcinoma Market Size by Line of Therapies
- 14.4.3. Market Size by First Line of Therapies
- 14.4.4. Market Size by Second Line of Therapies
- 14.5. France Market Size
- 14.5.1. Total Market size of Hepatocellular Carcinoma
- 14.5.2. Hepatocellular Carcinoma Market Size by Line of Therapies
- 14.5.3. Market Size by First Line of Therapies
- 14.5.4. Market Size by Second Line of Therapies
- 14.6. Italy Market Size
- 14.6.1. Total Market size of Hepatocellular Carcinoma
- 14.6.2. Hepatocellular Carcinoma Market Size by Line of Therapies
- 14.6.3. Market Size by First Line of Therapies
- 14.6.4. Market Size by Second Line of Therapies
- 14.7. Spain Market Size
- 14.7.1. Total Market size of Hepatocellular Carcinoma
- 14.7.2. Hepatocellular Carcinoma Market Size by Line of Therapies
- 14.7.3. Market Size by First Line of Therapies
- 14.7.4. Market Size by Second Line of Therapies
- 14.8. United Kingdom Market Size
- 14.8.1. Total Market size of Hepatocellular Carcinoma
- 14.8.2. Hepatocellular Carcinoma Market Size by Line of Therapies
- 14.8.3. Market Size by First Line of Therapies
- 14.8.4. Market Size by Second Line of Therapies
- 14.9. Japan: Market Outlook
- 14.9.1. Total Market size of Hepatocellular Carcinoma
- 14.9.2. Hepatocellular Carcinoma Market Size by Line of Therapies
- 14.9.3. Market Size by First Line of Therapies
- 14.9.4. Market Size by Second Line of Therapies
15. Market Drivers
16. Market Barriers
17. Appendix
18. Report Methodology
- 18.1. Sources Used
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Summary:
Get latest Market Research Reports on Hepatocellular carcinoma (HCC). Industry analysis & Market Report on Hepatocellular carcinoma (HCC) is a syndicated market report, published as Hepatocellular carcinoma (HCC)- Market Insights, Epidemiology and Market Forecast-2028. It is complete Research Study and Industry Analysis of Hepatocellular carcinoma (HCC) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
